Modulators for Treatment of Cystic Fibrosis: Effectiveness and Value

Voting Questions for May 17, 2018 Public Meeting

These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.

Comparative Clinical Effectiveness

1) For individuals with approved gating, non-gating, and residual function mutations (including but not limited to G551D and R117H), is the evidence adequate to demonstrate that the net health benefit of treatment with Kalydeco (ivacaftor) with best supportive care is greater than that of best supportive care alone?
   Yes  No

2) For individuals who are homozygous for the F508del mutation, is the evidence adequate to demonstrate that the net health benefit of treatment with Orkambi (lumacaftor/ivacaftor) with best supportive care is greater than that of best supportive care alone?
   Yes  No

3) For individuals who are homozygous for the F508del mutation, is the evidence adequate to demonstrate that the net health benefit of treatment with Symdeko (tezacaftor/ivacaftor) with best supportive care is greater than that of best supportive care alone?
   Yes  No

4) For individuals who are homozygous for the F508del mutation, is the evidence adequate to distinguish the net health benefit between treatment with Symdeko with best supportive care and Orkambi with best supportive care?
   Yes  No

5) For individuals who are candidates for Symdeko combination therapy because they carry one F508del mutation and residual function mutation that is potentially responsive to Symdeko, is the evidence adequate to demonstrate that the net health benefit of treatment with Symdeko with best supportive care is greater than that of best supportive care alone?
   Yes  No
Other Benefits – For Discussion during the Public Meeting

At the public meeting of Midwest CEPAC, panel members will be asked to comment on which of the following Other Benefits they find important to consider in thinking about the overall value of the three drugs under study.

When compared to best supportive care, does Kalydeko, Orkambi, or Symdeko offer one or more of the following “other benefits”? (yes, no, uncertain)

a. This intervention offers reduced complexity that will significantly improve patient outcomes.
b. This intervention will reduce important health disparities across racial, ethnic, gender, socioeconomic, or regional categories.
c. This intervention will significantly reduce caregiver or broader family burden.
d. This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients who have failed other available treatments.
e. This intervention will have a significant impact on improving patients’ ability to return to work and/or their overall productivity.
f. This intervention will have a significant positive impact outside the family, including on schools and/or communities.
g. This intervention will have a significant impact on the entire “infrastructure” of care, including effects on screening for affected patients, on the sensitization of clinicians, and on the dissemination of understanding about the condition, that may revolutionize how patients are cared for in many ways that extend beyond the treatment itself.
h. There are other important benefits or disadvantages that should have an important role in judgments of the value of this intervention: ________________.

Contextual Considerations – For Discussion during the Public Meeting

At the public meeting of Midwest CEPAC, panel members will be asked to comment on which of the following Contextual Considerations they find important to consider in thinking about the overall value of the three drugs under study.

Are any of the following contextual considerations important in assessing Kalydeco’s, Orkambi’s, or Symdeko’s long-term value for money in patients? (yes, no, uncertain)

a. This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.
b. This intervention is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness.
c. This intervention is the first to offer any improvement for patients with this condition.
d. Compared to best supportive care, there is significant uncertainty about the long-term risk of serious side effects of this intervention.
e. Compared to best supportive care, there is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.
f. There are additional contextual considerations that should have an important role in judgments of the value of this intervention: ________________________.
Long-Term Value for Money

6) For individuals with approved gating, non-gating, and residual function mutations (including but not limited to G551D and R117H), given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering other benefits and contextual considerations, what is the long-term value for money of Kalydeco with best supportive care compared with best supportive care alone?

   High   Intermediate   Low

7) For individuals who are homozygous for the F508del mutation, given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering other benefits and contextual considerations, what is the long-term value for money of Orkambi with best supportive care compared with best supportive care alone?

   High   Intermediate   Low

8) For individuals who are homozygous for the F508del mutation, given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering other benefits and contextual considerations, what is the long-term value for money of Symdeko with best supportive care compared with best supportive care alone?

   High   Intermediate   Low

9) For individuals who are candidates for Symdeko because they carry one F508del mutation and residual function mutation that is potentially responsive to Symdeko, given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering other benefits and contextual considerations, what is the long-term value for money of Symdeko with best supportive care compared with supportive care alone?

   High   Intermediate   Low